A Phase II Study of BMS-354825 in Subjects With Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2012
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms START-A
- 07 Jun 2017 Biomarkers information updated
- 08 Nov 2012 Planned number of patients changed from 150 to 256 as reported by EudraCT.
- 09 Mar 2010 Patient numbers amended from 174 to 197 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History